Angiogenesis research has grown extensively over the past few decades with the recognition that angiogenesis plays a key role in embryonic development, wound healing, and also pathological conditions such as tumor metastasis. Numerous in vitro angiogenesis assays have been designed to mimic in vivo angiogenesis process. The in vitro assays are quick, simple, quantitative, and cost-effective, and have thereby played valuable roles in evaluation of the effects of test compounds on angiogenesis. However, each in vitro assay represents an individual step of a complex angiogenic cascade. Furthermore, significant diversities exist within endothelial cell types and within basement membrane extracts used in the assays. Thus, choosing appropriate cell types and assay conditions that most closely resemble the disease-specific angiogenesis being studied is essential to obtain meaningful results. Performing multiple in vitro assays together should also be considered to get data that is translatable from the preclinical to the clinical stage. For these reasons, increasing our understanding of in vitro assays is necessary for proper assay performance as well as correct interpretation of the results. Here we discuss two main critical factors regarding endothelial cell types and basement membrane extracts that are known to largely affect in vitro angiogenesis assays. We also introduce recent improvements in the most widely-used in vitro angiogenesis assays, which are 2-dimensional (2D) tube formation assays and 3-dimensional (3D) spheroid angiogenesis assay.
INTRODUCTION
Blood vessel formation, a highly organized sequence of cellular events, is initiated with activation of endothelial cells (ECs) followed by proliferation, sprouting, migration, tube formation, and maturation. Two fundamental processes of blood vessel formation are vasculogenesis and angiogenesis. Vasculogenesis refers to the de novo process of new vessel formation by migration and differentiation of endothelial progenitors into endothelial cells (ECs), whereas angiogenesis refers to the extension of pre-existing blood vessels through EC sprouting and subsequent stabilization by pericytes 1, 2 . Angiogenesis plays an important role in not only embryonic development but also adult reproductive function and wound healing 3 . Furthermore, abnormal angiogenesis is associated with many pathological conditions such as diabetic retinopathy, rheumatoid arthritis, and tumor progression. Thus, exploring key molecular mechanisms of angiogenesis has become one of the most important biomedical research areas because drugs to control angiogenesis hold great promise in overcoming vascular malformation-associated diseases, especially cancer 4 .
During drug development, in vivo animal study is necessary to demonstrate the effects of drug candidates on physiological function and systemic interaction between organs. However, ethical and cost issues have raised concerns regarding animal experiments 5 . Therefore, in vitro assays are carried out to screen effective drug candidates and obtain predictable data leading to the better decisions preceding in vivo studies. Numerous in vitro angiogenesis assays have been designed to mimic in vivo angiogenesis processes 5 . These assays are quick, simple, quantitative, and cost-effective, thereby have played as important role in evaluating the effects of test compounds on angiogenesis. In vitro angiogenesis assays have considerable flexibility. Test compounds can be added easily to the medium with/without growth factors. Transfected ECs can also be applied to determine the role of the target gene in angiogenic cascades.
However, each in vitro assay represents an individual step of a complex multi-step angiogenic process. Furthermore, significant diversities exist within endothelial cell types as well as within basement membrane extracts used in the assays 6 . Thus, choosing suitable in vitro assays with appropriate cell types and assay conditions that resemble closely the disease-specific angiogenesis being studied is important to obtain meaningful results. Also, performing multiple in vitro assays together should be considered to obtain data that translates to clinical studies. For these reasons, increasing our understanding of the critical factors that influence in vitro assays is necessary for proper performance of the assays and correct interpretation of the results. Here we discuss two main critical factors regarding endothelial cell types and basement membrane extracts that are known to largely influence in vitro angiogenesis assays. We also introduce recent improvements in the most popular 2D and 3D in vitro angiogenesis assays, which are tube formation assays and spheroid angiogenesis assay.
Angiogenesis Process
Angiogenesis is a tightly-regulated, multi-step process. The first step is the stimulation of ECs by angiogenic factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) 7 . They bind to their receptors on ECs, activating signal transduction pathways. Matrix metalloproteinases (MMPs) are released from activated ECs, and then breakdown the extracellular matrix (ECM), allowing ECs to migrate out of the pre-existing vessel wall 8 . Integrins expressed on the EC surface facilitate EC adhesion to the extracellular matrix and their migration 9 . Angiopoietin-2 released from activated ECs then binds to Tie-2 receptors on the ECs, resulting in vessel sprouting and tube formation 10 . Finally, ECs release platelet-derived growth factor (PDGF) that chemo-attracts pericyte precursors that become associated with endothelial cells, differentiate into pericytes, and finally stabilize the newly formed blood vessels 11 . During the multistep angiogenesis process, ECs go through a dynamic progression, in which they are proliferated, migrated, sprouted, and finally create tubular structures along with pericyte recruitment in a time-dependent manner. Current in vitro angiogenesis assays measure the angiogenic abilities of ECs regarding proliferation, migration, and formation of sprout and tubular structures. In vitro assays are performed in simpler conditions than what exist in vivo, and are applicable to study an individual property of ECs during angiogenic process. Thus, researchers should have considerable understanding of the critical factors affecting in vitro assays to obtain meaningful and translatable results.
Choice of ECs
Until relatively recently, the most commonly used human ECs for in vitro angiogenesis assays were human umbilical vein endothelial cells (HUVECs) because these cells can be easily isolated from human umbilical vein and cultured by common laboratory cell culture techniques 12 . However, the structural and functional diversity of endothelial cells have been largely investigated between different EC populations such as between arteries and veins, and between large and small vessels [13] [14] [15] . Now it is well recognized that there is considerable heterogeneity in EC populations derived from different organs and tissues. This heterogeneity is related to the microenvironmental conditions and the demands on endothelium in each organ 16 . The characteristics of different ECs can result in different responses to angiogenic stimuli 6 . Angiogenesis associated with aggravation of diseases commonly involves the microvessels rather than macrovessels. Thus, use of ECs from a conduit artery or vein may lead to inaccurate and inconclusive results for pathological angiogenesis. As isolation techniques have been developed, types of human ECs available have extended from HUVECs to others such as human dermal microvascular endothelial cells (HDMECs), human hepatic sinusoidal endothelial cells (HCAECs), human pulmonary artery endothelial cells (HPAECs), and human brain microvascular endothelial cells (HBMECs), all of which enable researchers to use ECs more suited to specific research purposes.
Recently, human endothelial colony forming cells (ECFCs), also known as endothelial progenitor cells (EPCs), have been applied to angiogenesis assays 17, 18 . EPCs are the circulating precursors of ECs derived from bone marrow. Since their discovery by Asahara et al at in 1997, two main subpopulations of EPCs have been identified 19 . Early-EPCs promote angiogenesis by secreting pro-angiogenic factors rather than differentiating into endothelium 20 . In contrast, late-EPCs, here called ECFCs, have been shown to have proliferative and differentiative potential for neovascularization in both in vitro and in vivo assays 21 . Mature ECs such as HUVECs normally lose these phenotypic expressions and molecular markers progressively as the passage numbers increase 22 . Whereas, ECFCs maintain robust proliferation and differentiation capacities compared with mature ECs 23 .
ECFCs contribute to new blood vessel formation in many post-natal pathophysiological conditions. For instance, circulating ECFCs are recruited into sites such as ischemic tissues for vascular regeneration, where they are incorporated into the vascular endothelial lining and differentiate in situ into endothelial cells 24, 25 . It has also been reported that 40% of endothelial cells in tumor tissue are derived from ECFCs that originate from bone marrow 26 . Thus, application of ECFCs in in vitro angiogenesis assays can provide valuable insights to discover therapeutic angiogenesis modulators against abnormal angiogenic processes. Overall, use of ECs isolated from disease-related organs and tissues is very important to obtain meaningful results for targeting specific diseases. In addition, the passage number and culture conditions such as confluency influence the proliferation, migration, and tube formation of ECs 23, 27, 28 . Therefore, preliminary experiments to test cell condition as well as seeding density per well should precede the performance of real assays to ensure consistency and reproducibility of the results.
Choice of Basement Membrane Extract
When performing in vitro assays, choice of basement membrane extract is important because the mechanisms by which ECs differentiate to form tubular structures are largely dependent upon the matrices on which cells are seeded. Pro-or anti-angiogenic effect varies with matrices containing different components. For example, CXCR2 receptor blocker shows a considerably weaker effect at interrupting tube formation on matrices containing abundant sulfate proteoglycans 29 . Growth factor reduced (GFR) matrix, which contains significantly fewer sulfate proteoglycans, however, demonstrates relatively more of the anti-angiogenic effect of CXCR2 receptor blocker. Thus, composition of basement membrane extract is critical in exploring the property of pro-and anti-angiogenesis.
Matrigel is most commonly-used matrix in in vitro and in vivo vascular formation experiments. However, it is not a desirable material for clinical use since it is derived from a murine tumor. Human-derived collagen and fibrin product are FDA-approved for clinical use. Previous study found that, in both collagen and fibrin, the degree of blood vessel formation was reduced at very high concentrations 30 . It may be due to the increase of the interference between adjacent fibrils in the higher concentration of matrix proteins.
The stiffness of matrices can also influence angiogenic potential of ECs. In a previous study, the correlation between type I collagen gel stiffness and angiogenic potential of ECs was assessed by adjusting pH of the collagen solution during polymerization. Smaller diameter of collagen fiber in higher pH increased gel stiffness 31 . The invasive potential of tubes formed by both HUVECs and human aortic endothelial cells (HAECs) into the stiff collagen gel was significantly reduced, even though HAECs showed higher angiogenic potential than HUVECs in high stiffness condition. 32 This suggest that ECM-related physical interaction might regulate angiogenic potential.
There is also variability of angiogenic degree by different preparations of the basement membrane extract. Lot-to-lot variations, even from the same vendor, can seriously affect the sensitivity of in vitro angiogenesis assays, resulting in different qualities of data. It may be advisable to test the lot(s) in the assay conditions after a change. Lastly, the optimal concentration and coating volume of matrix per well should be carefully decided before performing the assays because both factors may influence the angiogenic potentials of ECs 33 .
2D Tube Formation Assay
Since the in vitro tube formation assay was first described in 1988 by Kubota et al. 34 this assay have been widely used and has made significant contribution to discovery of angiogenesis-modulating drugs. Many laboratories use this assay to gather initial observations on the proor anti-angiogenic effect and to investigate the underlying cellular signaling pathways. To perform this assay, ECs are seeded onto a surface coated with basement membrane extract, such as collagen, fibrin, or Matrigel. Seeded cells are attached, migrated, and differentiated into the capillary-like tube structure. Progression of tube formation can be observed over 6 to 24 hours using conventional microscopy or realtime cell recorder. The degree of tube formation can be analyzed by quantification of tube number, branch number, loop number, and/or total or average tube length. Test compounds can be treated by mixing them into the cell suspension solution. Pre-stimulation of the cells with test compounds can also be applied for the purpose of long-term exposure. To get accurate results, it is highly recommended to use the control group that is composed of basal, positive, and negative control. Positive or negative control can be obtained by treatment with wellestablished stimulators or inhibitors of angiogenesis. The control group is also used to verify whether the cell condition and assay protocol are optimal.
This assay has many advantages. It is relatively easy, quick, and reliable. Any growth factors and test compounds can be added exogenously to the medium. Various cell types including transfected or knockdown cells can be applied to the assay. This assay can be run in a relatively high-throughput manner for screening potent angiogenesis modulators. However, several points should be improved to increase utilization of the assay. The tubular structure from single-cell suspension gradually increased followed by degradation in a timedependent manner. However, most of studies detect the degree of tube formation at only one or two time points because of the inconvenience of the experimental schedule. Indeed, time-lapse video images provide evidence of time-dependent dynamic progression of the initiation, elongation, and degradation of tubular structures. For example, the tube number formed by ECFCs increased for the first 12 hours and decreased after that time 17 . Treatment by VEGF, the most famous proangiogenic factor, increased tube number significantly for the first six hours but rapidly decreased at later time points compared with the untreated control. Because the degree of tube formation can be in an increasing or decreasing phase according to the observation time points, continuous measurement of progression of tube formation may be necessary for in-depth evaluation of pro-and anti-angiogenic properties.
Another drawback of the in vitro tube formation assay is related to image size to be analyzed. Typically, the degree of tube formation is analyzed using microscope images taken with a 10x objective lens. However, the image from a 10x objective lens is too small to observe tubular structures distributed over the well. For this reason, some researchers perform the assay analyze 8-10 images per well to obtain the average values of tube number and length. However, taking many images by microscopy poses stress to the cells due to changes in temperature and shaking motion, which can interfere with formation and duration of tubular structures. To overcome this limitation, imagestitching software along with an automatic positioning and focusing microscope can be applied to obtain larger image size without undue stress to ECs during tube formation 17 . Four side-by-side (2X2) stitchedimage produced by a 4x objective lens is 25-fold bigger than one image from a 10x object lens (Figure 1 ). This image-stitching process can minimize bias and increase the accuracy of the results by analyzing a larger area.
3D Spheroid Angiogenesis Assay
Most in vitro angiogenesis assays replicate a part of angiogenesis process by ECs seeded in 2D culture plates. Although 2D in vitro angiogenesis assays have been widely used to evaluate pro-or anti-angiogenic properties, traditional 2D assay systems have several limitations. 2D culture systems cannot mimic the mechanical and biochemical signals present in 3D in vivo environments 35 . Furthermore, 2D culture systems cause a loss of originality of cells. For example, 2D-cultured ECs progressively lose their differentiated phenotype as demonstrated by reduced expression of CD34 and several signals that govern cellular processes 22, 36 . Thus, 2D culture assay systems may provide insufficient data, which may be responsible for discrepancies between the effects of angiogenic-modifying drugs in in vitro assays and what is expected in clinical trials. To address these issues associated with 2D culture condition, 3D assay system has been garnered more attention among researchers 37 . 3D systems can provide an in vivo-like environment to the cells, which enhance cell-to-cell and cell-to-ECM interactions, therefore better mimicking in vivo architecture of organs and tissues 38 . 3D systems enable generation of results that bridge the gap between conventional 2D culture assays and in vivo animal models 39, 40 .
3D spheroid angiogenesis assay systems have been developed 41, 42 . Sprouting followed by tubular structure formation from spheroids of ECs reflects the in vivo neo-vascularization process 43, 44 . Spheroids can be generated by the hanging drop method 45 . Briefly, single-cell suspension of 1,000 ECs in a 20-25 µL droplet are pipetted on the inside of a lid of cell-culture dishes. Gravity-enforced self-aggregation is facilitated by inverting the lid onto a phosphate-buffered solution (PBS)-filled dish. After 12-24 hours, the lid is inverted, and spheroids are collected in PBS. Spheroids are mixed with neutralized type I collagen solution, quickly seeded into the well plates, and covered with basal medium.
In some experiments, test compounds or growth factors are added to the basal medium. The plates are placed in an incubator (37°C and 5% CO 2 ), and sprout formation is observed in time-dependent images. 45 The angiogenic potential is quantified by counting the number and cumulative length of sprouts generated from individual spheroids. Five randomly-selected spheroids are analyzed per experimental group. The 3D spheroid angiogenesis assay can be easily and quickly carried out within two days using common laboratory techniques. Current 3D spheroid angiogenesis assays mostly utilize ECs, mainly HUVECs, to focus on the behavior of ECs during angiogenesis. However, blood vessels are composed of two types of vascular cells: ECs and pericytes. Elaborate bi-directional interaction between ECs and pericytes is essential for blood vessel formation. During angiogenesis, ECs are responsible for sprout formation followed by generation of new tubular structures, while pericytes are responsible for maturation of the nascent blood vessels by enveloping their surfaces. Several diseases, such as hereditary stroke, diabetic retinopathy, and venous malformation, are associated with altered pericyte density or decreased pericyte attachment to the endothelium 46 . Some 3D angiogenesis assays have employed co-culture of ECs and perivascular cells such as vascular smooth muscle cells to reflect in vivo angiogenesis process 47 .
A co-culture 3D spheroid model as an in vitro representation assembly of blood vessels was first demonstrated by Korff et al. 48 in 2001. They formed spheroids by combination of HUVECs and human umbilical artery smooth muscle cells (HUSMCs), and observed an unexpected decrease of sprouting formation form co-cultured spheroids. It may have been due to the cell types that were used. They and others suggested that mature ECs (HUVECs) progressively lose their ability to proliferate and differentiate, which negatively affects their angiogenesis response 49, 50 . Also, mature perivascular cells (HUSMCs) can cause endothelial cell inactivation through abrogation of vascular endothelial growth factor (VEGF) responsiveness 48 .
To improve the co-culture 3D spheroid angiogenesis assay system, we recently developed co-culture spheroids by combining two vascular progenitors: endothelial colony forming cells (ECFCs) and mesenchymal stem cells (MSCs). ECFCs, also called late-EPCs, are circulating precursors of ECs. ECFCs have been reported to have robust proliferation capacity compared to mature ECs such as HUVECs, which enable to overcome the limitation of ECs 23 . MSCs are pluripotent stem cells that have the capacity to differentiate into pericytes, thereby contributing to the angiogenic process [51] [52] [53] . In previous studies, coculture of ECFCs and MSCs showed enhanced in vitro tube formation 17 . Co-implantation of ECFCs and MSCs into immune-deficient mice generated perfused blood vessels in vivo and improved reperfusion of ischemic tissues 25, [54] [55] [56] . In the co-culture 3D spheroid assay system, ECFCs and MSCs are mixed to form co-culture spheroids and embedded in type I collagen gel to reflect an in vivo 3D environment 45 . For effective cell tracking during the sprouting process, each cell type can be fluorescently labeled and monitored using a fluorescence microscope. In comparison experiment, ECFCs+MSCs spheroids generated greater sprout number and cumulative sprout length compared with ECFCs-only spheroids (Figure 2) 45 . Bevacizumab, an FDA-approved angiogenesis inhibitor, was tested with ECFCs+MSCs spheroid assay system to verify its potential to screen anti-angiogenic drugs. The IC 50 value for ECFCs+MSCs spheroids compared to the ECFCs-only spheroids was closer to the effective plasma concentration of bevacizumab obtained from the xenograft tumor mouse model, suggesting that the 3D ECFCs+MSCs spheroid angiogenesis assay system is relevant to physiologic angiogenesis, and can predict an effective plasma concentration in advance of animal experiments 45 .
CONCLUSION
Drugs that modify angiogenesis hold great promise as potential treatment options for vascular malformation-associated diseases. Many pharmaceutical companies and research institutes have spent large effort, time, and money on discovering angiogenesis-modulating drugs. Despite of considerable efforts, few drugs have entered into clinical trials. This may be because the preclinical in vitro assay systems do not have sufficient sensitivity for identifying potential drug candidates that can effectively modify in vivo angiogenic events. Until now, only a few drugs, such as Bevacizumab (Avastin), Axitinib (Inlyta), Sunitinib (Sutent) and Ziv-aflibercept (Zaltrap), have been approved for clinical use. To minimize the gap between in vitro experimental data and in vivo clinical data, it is crucial to choose suitable in vitro assay systems with appropriate cell types and optimal assay conditions that reflect closely the disease-related angiogenesis under study. Furthermore, to fully interpret the effects of a test compounds on angiogenesis, it is necessary to perform multiple in vitro assays designed to replicate different steps of the complex angiogenic cascade. Recently, 3D microfluidic systems have been adopted in vascular research [57] [58] [59] . These systems have an advantage of providing 3D physical interactions of cellto-cell and cell-to-ECM in the scaffolds during generation of tubular sturctures [60] [61] [62] . However, they may require relatively specific techniques and equipment, and special training to utilize microfluidic systems. On the other hand, improvements to current in vitro angiogenesis assays like co-culture of ECs with pericytes or immune cells could be a valuable approach to enhance the value of preclinical in vitro studies. 
